Overview

NCI Definition [1]:
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.

Tiragolumab has been investigated in 17 clinical trials, of which 17 are open and 0 are closed. Of the trials investigating tiragolumab, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), 6 are phase 2 (6 open), and 4 are phase 3 (4 open).

PD-L1 Expression, PD-L1 High Expression, and PD-L1 Low Expression are the most frequent biomarker inclusion criteria for tiragolumab clinical trials.

Esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in tiragolumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tiragolumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tiragolumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mtig7192a, rg6058, anti-tigit monoclonal antibody mtig7192a, tiragolumab, tiragolumab
Drug Target(s) [2]:
TIGIT
NCIT ID [1]:
C152656

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.